KjG The Korean Journal of Gastroenterology Korean J Gastroenterol 1598-9992 2233-6869 Korean Society of Gastroenterology 10.4166/kjg.2014.64.4.250 kjg-64-250 Research Update Can Noninvasive Fibrosis Assessment Predict Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients? KimMi Na KimJun Hyung KimSeung Up Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Correspondence to: Seung Up Kim, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Korea. Tel: +82-2-2228-1982, Fax: +82-2-393-6884, E-mail: ksukorea@yuhs.ac 10 2014 04 10 2014 64 4 250 252 Copyright © 2014 Korean Ophthalmological Society 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Article

Noninvasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin for Chronic Hepatitis C.

 References Ogawa E Furusyo N Shimizu M Noninvasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C Antivir Ther 2014 doi: 10.3851/IMP2805. [Epub ahead of print] Seeff LB Natural history of chronic hepatitis C Hepatology 2002 365 Suppl 1S35S46 Wedemeyer H Jensen DM Godofsky E Mani N Pawlotsky JM Miller V Definitions/Nomenclature Working Group∗ of the HCV DrAG (HCV Drug Development Advisory Group), under the aus-pices of the Forum for Collaborative HIV Research Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents Hepatology 2012 5623982403 Zeuzem S Andreone P Pol S REALIZE Study Team Telaprevir for retreatment of HCV infection N Engl J Med 2011 36424172428 Cammà C Petta S Enea M WEF Study Group Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C Hepatology 2012 56850860 Bacon BR Gordon SC Lawitz E HCV RESPOND-2 Investigators Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 2011 36412071217 Furusyo N Ogawa E Nakamuta M Kyushu University Liver Disease Study (KULDS) Group Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C J Hepatol 2013 59205212 Serfaty L Forns X Goeser T Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1 Gut 2012 6114731480 El-Serag HB Hepatocellular carcinoma: recent trends in the United States Gastroenterology 2004 1275 Suppl 1S27S34 Oka H Kurioka N Kim K Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis Hepatology 1990 124 Pt 1680687 Castera L Noninvasive methods to assess liver disease in patients with hepatitis B or C Gastroenterology 2012 14212931302.e4 Kim JH Kim MN Han KH Kim SU Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment Liver Int 2014 doi: 10.1111/liv.12628. [Epub ahead of print] Park MS Han KH Kim SU Noninvasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease Expert Rev Gastroenterol Hepatol 2014 8501511 Kang W Kim SU Ahn SH Noninvasive prediction of forthcoming cirrhosis-related complications World J Gastroenterol 2014 2026132623 Ogawa E Furusyo N Nakamuta M Kyushu University Liver Disease Study (KULDS) Group Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study Aliment Pharmacol Ther 2013 3810761085